The US Food and Drug Administration has approved the extension of dosing intervals for Regeneron’s EYLEA HD (aflibercept) up to every 20 weeks for patients with wet age-related macular degeneration ...
The trial will evaluate EC-104 fluocinolone acetonide (FA) extended release for the treatment of diabetic macular edema (DME). Eclipse Life Sciences has completed patient enrollment in its BETTIS-1 ...
MALBEC (NCT07440225) is a randomized, double-masked trial evaluating the safety and efficacy of MK-8748 at 2 dose levels versus control (aflibercept 2mg). Merck has initiated MALBEC, its phase 2b/3 ...
FDA fast-tracks RTx-015, an optogenetic gene therapy aiming to restore vision in late-stage retinitis pigmentosa. The US Food and Drug Administration (FDA) has granted regenerative medicine advanced ...
The Retina TL;DR with Dr. Weng: Unpacking photobiomodulation for dry AMD with Drs. Do, Lad, and Munk
In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Drs. Do, Lad, and Munk about the LIGHTSITE III trial data behind photobiomodulation and what ...
Images showed that Parkinson’s disease is associated with a thicker photoreceptor nuclear layer and a thinner layer of photoreceptor processes. An Australian study 1 reported that directional optical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results